BioVaxys Technology Corp. (CSE:BIOV)
Canada
· Delayed Price · Currency is CAD | Market Cap | 15.81M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.63M |
| Shares Out | 287.37M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 258,500 |
| Average Volume | 235,590 |
| Open | 0.0550 |
| Previous Close | 0.0500 |
| Day's Range | 0.0550 - 0.0550 |
| 52-Week Range | 0.0400 - 0.1000 |
| Beta | -0.17 |
| RSI | 50.32 |
| Earnings Date | Feb 28, 2025 |
About BioVaxys Technology
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant o... [Read more]
Financial Performance
Financial StatementsNews
Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies
VANCOUVER, BC , July 29, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage biopharmaceutical company developing a portfoli...